Narrow your search
Listing 1 - 3 of 3
Sort by

Book
Handbook of Neuroemergency Clinical Trials.
Authors: ---
ISBN: 0128040645 Year: 2017 Publisher: Saint Louis : Elsevier Science & Technology,


Multi
Handbook of neuroemergency clinical trials
Authors: ---
ISBN: 9780128041017 0128041013 9780128040645 0128040645 Year: 2018 Publisher: London Elsevier Academic Press

Loading...
Export citation

Choose an application

Bookmark

Abstract

Handbook of Neuroemergency Clinical Trials, Second Edition, focuses on the practice of clinical trials in acute neuroscience populations, or what have been called neuroemergencies. Neuroemergencies are complex, life-threatening diseases and disorders, often with devastating consequences, including death or disability. The overall costs are staggering in terms of annual incidence and costs associated with treatment and survival, yet despite their significance as public health issues, there are few drugs and devices available for definitive treatment. The book focuses on novel therapies and the unique challenges their intended targets pose for the design and analysis of clinical trials. This volume provides neurologists, neuroscientists, and drug developers with a more complete understanding of the scientific and medical issues of relevance in designing and initiating clinical development plans for novel drugs intended for acute neuroscience populations. The editors provide the best understanding of the pitfalls associated with acute CNS drug development and the best information on how to approach and solve issues that have plagued drug development.

Handbook of neuroemergency clinical trials
Authors: ---
ISBN: 9780126480825 0126480826 0080454356 9780080454351 1280630787 9781280630781 9780080543109 0080543103 9786610630783 9780120885237 0120885239 Year: 2006 Publisher: Amsterdam ; Boston : Elsevier Academic Press,

Loading...
Export citation

Choose an application

Bookmark

Abstract

During the 1990's, scientific advances in understanding the mechanisms and pathophysiology of acute central nervous system injury were offset by a history of disappointing results from Phase III clinical trials of novel neuroprotective drugs. Numerous novel compounds were "tested,? and seemingly fell by the wayside. This book is intended to focus on novel therapies and the unique challenges their intended targets pose for the design and analysis of clinical trials. The authors explore the issues facing research in this area and the strategies that might lead to future success in this critical

Listing 1 - 3 of 3
Sort by